This is the authors' abstract. We don't add key points for this paper.
TCID50/mL, either in liquid or lyophilized forms. The liquid formulation was suitable and safe for mucosal vaccination and was stable for 1 week at 37 °C. Both the liquid and lyophilized formulations were stable after 6 months of storage at 4 °C. We demonstrate that the instillation of the adenoviral vector through the nasal cavity can confer protection to chickens against a lethal challenge with NDV. Overall, a manufacturing process for the adenovirus-vectored vaccine was developed, and protective doses were determined using a convenient route of delivery. Formulation and storage conditions were established, and quality control protocols were implemented.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Farnós et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: